Company research
BOSTON SCIENTIFIC CORP
CIK 885725Updated Sep 24, 2026
SecurityBSX · NYSE · equity
BSX price & chart
Loading TradingView…
NYSE:BSX on TradingView ↗About the company
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at
In the news
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 4, 2026 in Boston Scientific Corporation Lawsuit - BSX ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX ↗
BSX Deadline: BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 43,673,000,000Source | 39,395,000,000Source | 35,136,000,000Source | 32,469,000,000Source |
| Property, Plant and Equipment, NetUSD | 4,036,000,000Source | 3,294,000,000Source | 2,859,000,000Source | 2,446,000,000Source |
| GoodwillUSD | 18,282,000,000Source | 17,089,000,000Source | 14,387,000,000Source | 12,920,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,019,000,000Source | 6,684,000,000Source | 6,003,000,000Source | 5,902,000,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,965,000,000Source | 414,000,000Source | 865,000,000Source | 928,000,000Source |
| Inventory, NetUSD | 2,943,000,000Source | 2,810,000,000Source | 2,484,000,000Source | 1,867,000,000Source |
| Assets, CurrentUSD | 8,794,000,000Source | 6,920,000,000Source | 6,514,000,000Source | 5,760,000,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 660,000,000Source | 831,000,000Source | 621,000,000Source | 731,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 465,000,000Source | 449,000,000Source | 439,000,000Source | 386,000,000Source |
| Other Assets, NoncurrentUSD | 1,866,000,000Source | 1,754,000,000Source | 1,531,000,000Source | 1,500,000,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 17,000,000Source | 17,000,000Source | 17,000,000Source | 17,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | 5,571,000,000Source | 2,673,000,000Source | 819,000,000Source | -750,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -610,000,000Source | 275,000,000Source | 49,000,000Source | 269,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 24,233,000,000Source | 21,770,000,000Source | 19,282,000,000Source | — |
| Additional Paid in Capital, Common StockUSD | 21,505,000,000Source | 21,056,000,000Source | 20,647,000,000Source | 20,289,000,000Source |
| Liabilities and EquityUSD | 43,673,000,000Source | 39,395,000,000Source | 35,136,000,000Source | 32,469,000,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,439,000,000Source | 6,399,000,000Source | 4,933,000,000Source | 3,803,000,000Source |
| Operating Lease, Liability, CurrentUSD | 90,000,000Source | 81,000,000Source | 76,000,000Source | 61,000,000Source |
| Accounts Payable, CurrentUSD | 1,144,000,000Source | 960,000,000Source | 942,000,000Source | 862,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 446,000,000Source | 401,000,000Source | 390,000,000Source | 347,000,000Source |
| Deferred Income Tax Liabilities, NetUSD | 220,000,000Source | 155,000,000Source | 134,000,000Source | 144,000,000Source |
| Other Liabilities, NoncurrentUSD | 2,405,000,000Source | 1,870,000,000Source | 1,967,000,000Source | 2,035,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 239,000,000Source | 233,000,000Source | 248,000,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,201,000,000Source | 2,773,000,000Source | 2,646,000,000Source | 2,160,000,000Source |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | — | — | — | -1,000,000Source |
| Deferred Revenue, CurrentUSD | 313,000,000Source | 306,000,000Source | 266,000,000Source | 220,000,000Source |
| Deferred Tax Liabilities, NetUSD | 220,000,000Source | 155,000,000Source | 134,000,000Source | 144,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 2,892,000,000Source | 1,846,000,000Source | 1,592,000,000Source | 698,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,368,000,000Source | 1,269,000,000Source | 1,196,000,000Source | 1,136,000,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 299,000,000Source | 266,000,000Source | 233,000,000Source | 220,000,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 269,000,000Source | 351,000,000Source | 238,000,000Source | 220,000,000Source |
| Increase (Decrease) in InventoriesUSD | 188,000,000Source | 228,000,000Source | 660,000,000Source | 321,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | -12,000,000Source | -90,000,000Source | 73,000,000Source | -7,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 4,534,000,000Source | 3,435,000,000Source | 2,503,000,000Source | 1,526,000,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 1,593,000,000Source | 4,640,000,000Source | 1,811,000,000Source | 1,542,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,640,000,000Source | -5,687,000,000Source | -2,574,000,000Source | -2,011,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -84,000,000Source | -20,000,000Source | -30,000,000Source | -70,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 876,000,000Source | 790,000,000Source | 711,000,000Source | 588,000,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -395,000,000Source | 1,814,000,000Source | 5,000,000Source | -548,000,000Source |
| Dividends paid | — | — | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 7,000,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,541,000,000Source | -450,000,000Source | -70,000,000Source | -1,042,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,147,000,000Source | 606,000,000Source | 1,055,000,000Source | 1,126,000,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 319,000,000Source | 250,000,000Source | 259,000,000Source | 450,000,000Source |
| Income Taxes Paid, NetUSD | 561,000,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 42,000,000Source | -11,000,000Source | -4,000,000Source | -9,000,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 897,000,000Source | 856,000,000Source | 828,000,000Source | 803,000,000Source |
| DepreciationUSD | 471,000,000Source | 412,000,000Source | 367,000,000Source | 333,000,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | 0Source | 0Source | -22,000,000Source |
| Gain (Loss) on InvestmentsUSD | 139,000,000Source | -79,000,000Source | -59,000,000Source | -1,000,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | 0Source | 0Source | -22,000,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 0Source | — |
| GoodwillUSD | 18,282,000,000Source | 17,089,000,000Source | 14,387,000,000Source | 12,920,000,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 46,000,000Source | 386,000,000Source | 58,000,000Source | 132,000,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 46,000,000Source | 386,000,000Source | 58,000,000Source | 132,000,000Source |
| Income Tax Expense (Benefit)USD | 493,000,000Source | 436,000,000Source | 393,000,000Source | 443,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -6,000,000Source | -8,000,000Source | 1,000,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 2,898,000,000Source | 1,853,000,000Source | 1,570,000,000Source | 642,000,000Source |
| Nonoperating Income (Expense)USD | — | — | -358,000,000Source | -508,000,000Source |
| Operating ExpensesUSD | 10,241,000,000Source | 8,887,000,000Source | 7,553,000,000Source | 7,078,000,000Source |
| Other Nonoperating Income (Expense)USD | -228,000,000Source | -321,000,000Source | -93,000,000Source | -38,000,000Source |
| Other Operating Income (Expense), NetUSD | — | 16,000,000Source | 93,000,000Source | 38,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 178,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 20,074,000,000Source | 16,747,000,000Source | 14,240,000,000Source | 12,682,000,000Source |
| Cost of RevenueUSD | 6,221,000,000Source | 5,257,000,000Source | 4,345,000,000Source | 3,956,000,000Source |
| Selling, General and Administrative ExpenseUSD | 6,887,000,000Source | 5,984,000,000Source | 5,190,000,000Source | 4,520,000,000Source |
| Operating Income (Loss)USD | 3,613,000,000Source | 2,603,000,000Source | 2,343,000,000Source | 1,649,000,000Source |
| Other Nonoperating Income (Expense)USD | -228,000,000Source | -321,000,000Source | -93,000,000Source | -38,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 3,385,000,000Source | 2,282,000,000Source | 1,985,000,000Source | 1,141,000,000Source |
| Income Tax Expense (Benefit)USD | 493,000,000Source | 436,000,000Source | 393,000,000Source | 443,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -6,000,000Source | -8,000,000Source | 1,000,000Source | — |
| Earnings Per Share, BasicUSD per share | 1.96Source | 1.26Source | 1.08Source | 0.45Source |
| Earnings Per Share, DilutedUSD per share | 1.94Source | 1.25Source | 1.07Source | 0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,480,400,000Source | 1,471,500,000Source | 1,453,000,000Source | 1,430,500,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,494,500,000Source | 1,485,900,000Source | 1,463,500,000Source | 1,439,700,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 897,000,000Source | 856,000,000Source | 828,000,000Source | 803,000,000Source |
| Current Income Tax Expense (Benefit)USD | 505,000,000Source | 526,000,000Source | 320,000,000Source | 451,000,000Source |
| Gain (Loss) on InvestmentsUSD | 139,000,000Source | -79,000,000Source | -59,000,000Source | -1,000,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Gross ProfitUSD | 13,854,000,000Source | 11,490,000,000Source | 9,896,000,000Source | 8,727,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -311,000,000Source | -261,000,000Source | -394,000,000Source | -1,119,000,000Source |
| Interest ExpenseUSD | 349,000,000Source | 305,000,000Source | 265,000,000Source | 470,000,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 2,898,000,000Source | 1,853,000,000Source | 1,570,000,000Source | 642,000,000Source |
| Nonoperating Income (Expense)USD | — | — | -358,000,000Source | -508,000,000Source |
| Operating ExpensesUSD | 10,241,000,000Source | 8,887,000,000Source | 7,553,000,000Source | 7,078,000,000Source |
| Other Operating Income (Expense), NetUSD | — | 16,000,000Source | 93,000,000Source | 38,000,000Source |
Offerings
Registration 333-293872
Filing attachments
tm266847d4_ex99-1.htm · S-4/A · 2026-03-30
EX-99.1 6 tm266847d4_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 14, 2026 appearing as Annex B to, and the reference to such opinion letter under the headings “Summary - Opinion of Penumbra’s Financial Advisor - Perella Weinberg Partners LP”, “The Merger - Penumbra’s Reasons for the Merger; Recommendation of the Penumbra Board”, “The Merger - Opinion of Penumbra’s Financial Advisor - Perella …
Read attachment ↗tm266847d4_ex99-2.htm · S-4/A · 2026-03-30
EX-99.2 7 tm266847d4_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V86171-TBD For Against Abstain!!!!!!!!! PENUMBRA, INC. ONE PENUMBRA PLACE ALAMEDA, CA 94502 2. To approve, on a non-binding, advisory basis, the compensation that …
Read attachment ↗ex991-pressrelease.htm · 8-K · 2026-03-30
EX-99.1 2 ex991-pressrelease.htm EX-99.1 Document Exhibit 99.1 HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings presented at ACC.26 and simultaneously publ…
Read attachment ↗ex992-pressrelease.htm · 8-K · 2026-03-30
EX-99.2 3 ex992-pressrelease.htm EX-99.2 Document Exhibit 99.2 CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at …
Read attachment ↗tm266847d2_ex99-1.htm · S-4 · 2026-02-27
EX-99.1 5 tm266847d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 14, 2026 appearing as Annex B to, and the reference to such opinion letter under the headings “Summary - Opinion of Penumbra’s Financial Advisor - Perella Weinberg Partners LP”, “The Merger - Penumbra’s Reasons for the Merger; Recommendation of the Penumbra Board”, “The Merger - Opinion of Penumbra’s Financial Advisor - Perella…
Read attachment ↗tm266847d2_ex99-2.htm · S-4 · 2026-02-27
EX-99.2 6 tm266847d2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V86171-TBD For Against Abstain!!!!!!!!! PENUMBRA, INC. ONE PENUMBRA PLACE ALAMEDA, CA 94502 2. To approve, on a non-binding, advisory basis, the compensation that …
Read attachment ↗